{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T22:07:53Z","timestamp":1783462073849,"version":"3.55.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T00:00:00Z","timestamp":1669161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Spinal muscular atrophy (SMA) affects one in 7,500\u201310,000 newborns. Before the era of disease-modifying therapies, it used to be the major genetic cause of mortality in infants. Currently, there are three therapies approved for SMA, including two molecules modifying the splicing of the SMN2 gene and one gene therapy providing a healthy copy of the SMN gene with a viral vector. The best effects of any of these therapies are achieved when the treatment is administered in the presymptomatic stage of the disease, therefore newborn screening programs are being introduced in many countries. Patients identified in newborn screening might be eligible for gene therapy. However, gene therapy and the associated administration of steroids in newborns might interfere with the vaccination schedule, which includes live immunization against tuberculosis in some countries. The timing of gene therapy in patients who received live vaccinations has not yet been addressed neither in the clinical trials nor in the existing international guidelines. The Polish Vaccinology Association has developed the first recommendations for gene therapy administration in newborns who received live vaccination against tuberculosis. Their statement was implemented in the current guidelines for Polish SMA patients identified in the newborn screening program and might be helpful for medical professionals in other countries where live vaccine against tuberculosis is still in routine use in newborns.<\/jats:p>","DOI":"10.3389\/fneur.2022.890860","type":"journal-article","created":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T06:44:50Z","timestamp":1669185890000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Newborn screening and gene therapy in SMA: Challenges related to vaccinations"],"prefix":"10.3389","volume":"13","author":[{"given":"Katarzyna","family":"Kotulska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergiusz","family":"Jozwiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Jedrzejowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Gos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Ogrodnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Wysocki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Czajka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest","family":"Kuchar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/ana.24864","article-title":"Emerging therapies and challenges in spinal muscular atrophy","volume":"81","author":"Farrar","year":"2017","journal-title":"Ann Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","article-title":"Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review","volume":"12","author":"Verhaart","year":"2017","journal-title":"Orphanet J Rare Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1159\/000275492","article-title":"Incidence of spinal muscular atrophy in Poland\u2013more frequent than predicted?","volume":"34","author":"Jedrzejowska","year":"2010","journal-title":"Neuroepidemiology."},{"key":"B4","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13023-021-01783-8","article-title":"Newborn screening for spinal muscular atrophy in Germany: clinical results after 2 years","volume":"16","author":"Vill","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"B5","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell."},{"key":"B6","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/gt.2017.34","article-title":"How the discovery of ISS-N1 led to the first medical therapy for spinal muscular atrophy","volume":"24","author":"Singh","year":"2017","journal-title":"Gene Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1146\/annurev-genom-102319-103602","article-title":"Twenty-five years of spinal muscular atrophy research: from phenotype to genotype to therapy, and what comes next","volume":"21","author":"Wirth","year":"2020","journal-title":"Annu Rev Genomics Hum Genet."},{"key":"B8","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.nmd.2018.01.003","article-title":"Correlation between SMA type and SMN2 copy number revisited: An analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases","volume":"28","author":"Calucho","year":"2018","journal-title":"Neuromuscul Disord."},{"key":"B9","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.nmd.2021.08.009","article-title":"Spinal muscular atrophy: from rags to riches","volume":"31","author":"Mercuri","year":"2021","journal-title":"Neuromuscul Disord."},{"key":"B10","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.nmd.2021.03.007","article-title":"Newborn screening programs for spinal muscular atrophy worldwide: where we stand and where to go","volume":"31","year":"2021","journal-title":"Neuromuscul Disord"},{"key":"B11","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study","volume":"388","author":"Finkel","year":"2016","journal-title":"Lancet."},{"key":"B12","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","article-title":"Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy","volume":"86","author":"Chiriboga","year":"2016","journal-title":"Neurology."},{"key":"B13","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1056\/NEJMoa2009965","article-title":"Risdiplam in type 1 spinal muscular atrophy","volume":"384","author":"Baranello","year":"2021","journal-title":"N Engl J Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1007\/s40265-020-01410-z","article-title":"Risdiplam: first approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs."},{"key":"B15","unstructured":"2018"},{"key":"B16","doi-asserted-by":"publisher","first-page":"389","DOI":"10.3233\/JND-220789","article-title":"Spinal Muscular Atrophy - Is Newborn Screening Too Late for Children with Two SMN2 Copies?","volume":"9","author":"Schwartz","year":"2022","journal-title":"J Neuromuscul Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3233\/JND-190468","article-title":"Revised recommendations for the treatment of infants diagnosed with spinal muscular atrophy via newborn screening who have 4 copies of SMN2","volume":"7","author":"Glascock","year":"2020","journal-title":"J Neuromuscul Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N Engl J Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1136\/thorax-2020-BTSabstracts.17","article-title":"Five-year extension results of the phase 1 START trial of onasemnogene abeparvovec in spinal muscular atrophy","volume":"78","author":"Mendell","year":"2021","journal-title":"JAMA Neurol"},{"key":"B20","unstructured":"Long-Term Follow-up (LTFU) of onasemnogene abeparvovec gene therapy in Spinal Muscular Atrophy MendellJ FinkelR MercuriE StraussK DayJ KleynA 2021"},{"key":"B21","unstructured":"Onasemnogene abeparvovec gene therapy in presymptomatic spinal muscular atrophy (SMA): SPR1NT study update in children with three copies of SMN2 StraussK FarrarM MuntoniF SaitoK MendellJ ServaisL 2021 Muscular Dystrophy Association Virtual Clinical and Scientific Conference March 15-16.2021"},{"key":"B22","unstructured":"Onasemnogene abeparvovec gene therapy in presymptomatic spinal muscular atrophy (SMA): SPR1NT study update in children with two copies of SMN2 StraussK FarrarMA MuntonF SaitoK MendellJ ServaisL 2021 Muscular Dystrophy Association Virtual Clinical and Scientific Conference March 15-16.2021"},{"key":"B23","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/ppul.24203","article-title":"Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy","volume":"54","author":"Al-Zaidy","year":"2019","journal-title":"Pediatr Pulmonol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3233\/JND-190403","article-title":"AVXS-101 (Onasemnogene Abeparvovec) for SMA1: comparative study with a prospective natural history cohort","volume":"6","author":"Al-Zaidy","year":"2019","journal-title":"J Neuromuscul Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.jhep.2020.11.001","article-title":"Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy","volume":"74","author":"Chand","year":"2021","journal-title":"J Hepatol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jpeds.2020.11.054","article-title":"Thrombotic microangiopathy following onasemnogene abeparvovec for spinal muscular atrophy: a case series","volume":"231","author":"Chand","year":"2021","journal-title":"J Pediatr."},{"key":"B27","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1212\/WNL.94.15_supplement.5483","article-title":"Thrombotic Microangiopathy (TMA): a potential adverse reaction post Zolgensma (onasemnogene abeparvovec-xioi) therapy for Spinal Muscular Atrophy (SMA) (5483)","volume":"94","author":"Prabhu","year":"2020","journal-title":"Neurology."},{"key":"B28","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejpn.2020.07.001","article-title":"European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy","volume":"28","author":"Kirschner","year":"2020","journal-title":"Eur J Paediatr Neurol."},{"key":"B29","volume-title":"The Vaccine Handbook: A Practical Guide for Clinicians","author":"Marshall","year":"2018"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/S0140-6736(06)68507-3","article-title":"Effect of BCG, vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness","volume":"367","author":"Trunz","year":"2006","journal-title":"Lancet."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.3389\/fimmu.2017.01134","article-title":"What have we learnt about BCG vaccination in the last 20 years?","volume":"8","author":"Dockrell","year":"2017","journal-title":"Front Immunol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"eabn4002","DOI":"10.1126\/sciadv.abn4002","article-title":"Neonatal BCG vaccination is associated with a long-term DNA methylation signature in circulating monocytes","volume":"8","author":"Bannister","year":"2022","journal-title":"Sci Adv."},{"key":"B33","first-page":"335","article-title":"Complications of Bacillus Calmette-Guerin immunotherapy: review of 2602 patients and comparison of chemotherapy complications","volume":"310","author":"Lamm","year":"1989","journal-title":"Prog Clin Biol Res."},{"key":"B34","volume-title":"BCG Vaccine USP Insert","year":"2018"},{"key":"B35","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s00247-015-3464-z","article-title":"BCGitis and BCGosis in children with primary immunodeficiency\u2014imaging characteristics","volume":"46","author":"Shrot","year":"2016","journal-title":"Pediatr Radiol."},{"key":"B36","unstructured":"General Best Practice Guidelines for Immunization KrogerA BahtaL HunterP Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP)2022"},{"key":"B37","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/mus.27363","article-title":"Expert recommendations and clinical considerations in the use of onasemnogene abeparvovec gene therapy for spinal muscular atrophy","volume":"64","author":"Kichula","year":"2021","journal-title":"Muscle Nerve."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e1001012","DOI":"10.1371\/journal.pmed.1001012","article-title":"The BCG World Atlas: a database of global BCG vaccination policies and practices","volume":"8","author":"Zwerling","year":"2011","journal-title":"PLoS Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ijid.2022.04.023","article-title":"Effectiveness of Bacillus Calmette-Gu\u00e9rin vaccination against severe childhood tuberculosis in China: a case-based, multicenter retrospective study","volume":"121","author":"Liao","year":"2022"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.890860\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T10:54:50Z","timestamp":1728471290000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.890860\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,23]]},"references-count":39,"alternative-id":["10.3389\/fneur.2022.890860"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.890860","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,23]]},"article-number":"890860"}}